DAX-0,68 % EUR/USD+0,05 % Gold+0,85 % Öl (Brent)-1,93 %

+ 40% bei immune response !!!!NEWS!!!!!!! - 500 Beiträge pro Seite


AnzeigeAdvertisement

Beitrag schreiben

Begriffe und/oder Benutzer

 

die weichen sind gestellt ,jetzt gehts nur noch in eine
richtung.
die news:
Recent Clinical Data Suggest That REMUNE(TM) May
Help to Rebuild Immune System When Used Alone or in
Combination With Antiviral Drugs Against AIDS Virus


Thai Investigators to Propose REMUNE Monotherapy As
First Course of Treatment in HIV-Infected Individuals in Thailand

CARLSBAD, Calif., March 23 /PRNewswire/ -- The Immune Response Corporation
(Nasdaq: IMNR) announced today that recent clinical data suggest that
REMUNE(TM), its immune-based therapy to treat HIV infection, may induce HIV
immunity when used as a combination therapy with other antiviral drugs or when
used alone as a monotherapy. The data from multiple clinical trials were
presented at "An International Conference on HIV Vaccines -- An Annual Update
-- 2000" sponsored by the Thai Ministry of Public Health in Bangkok, Thailand.
Data were presented by Drs. Vernon Maino of Becton Dickinson, Fred
Valentine of New York University, Frances Gotch of Chelsea and Westminster
Hospital in London, Ron Moss of The Immune Response Corporation and Vina
Churdboonchart and Wisut Sukeepaisarncharoen of Thailand, all investigators of
clinical trials that examined the effects of REMUNE in HIV-infected patients.
An observation common to the multiple trials suggest that patients treated
with REMUNE in combination with antiviral drug therapy mount strong CD4 helper
T cell immune responses against HIV.
Data from the double-blind, placebo controlled study in Thailand, in which
REMUNE was examined as a monotherapy, were presented by Drs. Vina
Churdboonchart and Wisut Sukeepaisarncharoen. In this study, 297 HIV-1
infected patients who had never taken antiviral drug therapy received either
REMUNE or placebo during the 40-week trial period and were monitored for
several indicators of immune health and disease progression. The primary
measure of the number of CD4 helper T cells was significantly higher (p<0.05)
in the REMUNE treatment group. Furthermore, delayed type hypersensitivity
(DTH) skin tests and Western blots (test that detects antibodies against HIV)
performed on a random, pre-selected subset of patients indicated that
HIV-specific immunity was favored in patients treated with REMUNE (p<0.05).
"While antiviral drug therapy has been very beneficial to HIV patients in
keeping viral load in check, it has not generally proven to help rebuild the
immune system, which is ravaged by the virus. A common theme among the trial
results reported today suggests that REMUNE may help to restore immune
function to these patients. In fact, it is the T helper cells -- the very
immune cells that are destroyed by the virus -- that appear to re-establish
after treatment with REMUNE," said Dr. Vina Churdboonchart, principal
investigator for the trial in Thailand. "This is important because an
emerging consensus among HIV researchers is that immune health may be the key
to controlling HIV infection in the long term." Dr. Churdboonchart stated
that she is currently completing all documentation necessary for submission to
the Thai Minister of Public Health for commercial approval of REMUNE in
Thailand.
Dr. Sukeepaisarncharoen, a clinician in the Thai study, presented data
obtained during the follow-up period after the trial was completed on the same
subset of patients. He noted that 87% (59/68) of those patients tested 48
weeks after the trial`s end had stable (39 patients) or significantly
decreased (20 patients) amounts of HIV in the bloodstream, commonly referred
to as viral load. Furthermore, the decrease or stabilization of viral load
was associated with a sustained increase in number of CD4 helper T cells as
well as increased body weight.
"Several clinical parameters of immune health and disease progression
assessed in this trial and during the follow-up period suggest that REMUNE
alone may be a beneficial monotherapy in the treatment of HIV infection. This
is particularly important for HIV patients who do not have access to antiviral
drug therapy," said Dr. Churdboonchart who indicated that based on these and
previous results submitted to the Thai Ministry of Public Health, the Thai
investigators will propose that REMUNE monotherapy be administered to
HIV-infected individuals in Thailand as a first course of treatment.
The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
T-cell responses for the treatment of HIV and autoimmune diseases. In
addition, the Company is working on cancer vaccines and gene therapy.

NOTE: News releases are available through PR Newswire Company News On-
Call fax service. For a menu of available news releases or to retrieve a
specific release made by The Immune Response Corporation, please call
800-758-5804, extension 434675. Please retain these numbers for future
reference. Company information can also be located on the Internet Web Site:
http://www.imnr.com.

This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including, but not limited to, whether additional clinical trials will be
successfully concluded and whether REMUNE will be approved for marketing or be
successfully commercialized. Those factors are discussed more thoroughly in
The Immune Response Corporation`s SEC filings, including, but not limited to,
its report on Form 10-K for the year ended December 31, 1998 and subsequent
Forms 10-Q. The Company undertakes no obligation to publicly release the
result of any revisions to these forward-looking statements which may be made
to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.

REMUNE(TM) is a trademark of The Immune Response Corporation.

SOURCE The Immune Response Corporation


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um einen ältere Diskussionen, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier ein neue Diskussion.